Background: Previous studies have provided substantial evidence of the association of Aggregatibacter actinomycetemcomitans, and its highly leukotoxic JP2 genotype, with localized aggressive periodontitis (LAgP). The present study aims to evaluate presence of JP2 in individuals with LAgP after periodontal treatment.
C
haracterized by severe anatomic and physiologic destruction of periodontal structures supporting the first molars and/or incisors, localized aggressive periodontitis (LAgP) is an inflammatory disease that typically presents in adolescent individuals who are otherwise systemically healthy. 1,2 LAgP prevalence varies substantially among age groups and ethnicities; however, research evidence describes a more pronounced frequency of LAgP occurrence in adolescent populations of African ancestry, significantly more so than Hispanic and Caucasian populations. [3] [4] [5] Although the rationale behind this endemic remains to be elucidated, clinical investigations of Aggregatibacter actinomycetemcomitans (Aa), a resident bacterium of oral microbiota, may help provide possible explanations. [6] [7] [8] One such explanation examines the concept of two separate etiologies for LAgP: the first considers minimally leukotoxic genotypes of Aa as opportunistic pathogens across a number of ethnic groups worldwide; the second recognizes the highly leukotoxic JP2 genotype of Aa as an exogenous pathogen that exhibits racial tropism toward persons of African descent and is presumed to use interfamilial dissemination, 9 with the latter also found for Aa. 10, 11 Research has shown that individuals infected with this highly leukotoxic JP2 Aa have a higher risk of developing attachment loss than those infected with a non-JP2 genotype. 8 A similar study reports statistical significance between presence of the JP2 genotype and conversion from a healthy periodontal state to an LAgP diseased state with LAgP-susceptible African-American families. 12 Furthermore, a number of studies have associated the JP2 clone with more severe forms of LAgP. [13] [14] [15] The polymorphonuclear and monocyte cell-specific leukotoxin assembled by all Aa is produced in 10 to 20 times greater amounts in the JP2 genotype than in the minimally pathogenic genotype. 16 Additionally, Brogan et al. 16 describe this enhanced leukotoxicity as a consequence of a unique 530-bp deletion within the promoter region of leukotoxin operon. Subsequently, this deletion allows inclusion and participation of a second promoter in transcription of the leukotoxin gene, thereby leading to greater production of the toxin. 16 Thus, this organism appears to be of great toxicity and to have strong association with this disease.
Although previous studies on periodontitis treatment have shown significant correlations between the suppression of Aa presence and reductions in clinical parameters of AgP, [17] [18] [19] [20] persistence of the JP2 and non-JP2 genotypes after non-surgical treatment of patients with LAgP remains unclear. One study looked into JP2 genotype specifically after treatment of patients with periodontitis. Cortelli et al. 21 conducted a study in which a group of Brazilian patients with periodontitis harboring the JP2 and non-JP2 sequences were evaluated at baseline and reevaluated at 12 months after scaling and root planing (SRP), systemic antibiotics, and periodontal surgery. At 12 months, clinical measurements were significantly reduced in both groups; however, presence of the JP2 genotype negatively affected response to treatment. 21 Due to geographical changes on bacterial colonization of AgP, specifically in the Aa JP2 genotype, it is important to evaluate the potential reduction of this virulent clone in different populations/continents after no surgical therapy and long-term maintenance of such results after therapy.
A recent study has reported cross-sectional findings on prevalence of the JP2 and non-JP2 sequences of Aa in a cohort of 60 African-American children diagnosed with LAgP, of whom 83% (50) carried the JP2 genotype and 28.33% (17) carried the non-JP2 genotype. 22 Understanding host and bacterial response to periodontal treatment and disease progression/resolution during maintenance is crucial for the development of improved treatment protocols. Therefore, the objective of this longitudinal study is to investigate, within this population of patients with LAgP, the impact of mechanical periodontal therapy and a single dose of systemic antibiotic therapy on detection of JP2 and non-JP2 genotypes of Aa, as well as possible concomitant impacts on clinical manifestation of the disease over a 12-month period.
MATERIALS AND METHODS

Participant Population
Data reported herein were gathered from 60 AfricanAmerican patients with LAgP (31 males and 29 females, aged 5 to 25 years; baseline mean age: 13.25 -4.12 years); of these, 42 had LAgP affecting permanent dentition, and 18 had LAgP affecting primary dentition (see Table 1 Study inclusion criteria were as follows: 1) aged 5 to 25 years; 2) systemically in good health as evidenced by medical history; 3) diagnosis of LAgP according to criteria detailed in Armitage 2 and Albandar 1 ; 4) at least two sites with probing depth (PD) ‡5 mm; 5) bleeding on probing (BOP); 6) clinical attachment level (CAL) ‡2 mm; and 7) bone loss detected by radiographs, on first molars and/or incisors, but in no more than two teeth other than first molars and incisors. Exclusion criteria were as follows: 1) diagnosis of any systemic diseases or conditions that could influence characteristics or clinical presentation of LAgP (e.g., diabetes mellitus, blood disorders etc.); 2) use of antibiotics within 3 months prior to first visit, or use of any medications that could influence periodontal characteristics or interfere with response to periodontal treatment (e.g., cyclosporin, phenytoin); 3) pregnant and/or lactating women; and 4) smokers.
Clinical Examination and Sampling
At baseline and 3, 6, and 12 months, the following clinical parameters were measured at six sites per tooth by previously calibrated examiners (LMS and PH): 1) PD; 2) CAL; 3) BOP; and 4) plaque index (PI) using a probe § and stored using periodontal software. i Bitewing and periapical radiographs were taken to assess bone loss and further confirm diagnosis. Per § PCP-UNC15, Hu-Friedy, Chicago, IL. i Florida Probe, Gainesville, FL. patient, subgingival plaque was obtained from two LAgP diseased sites (PD ‡5 mm, BOP, CAL ‡2 mm, and radiographic bone loss), the deepest pockets of which were targeted, and from two healthy similar sites (interproximal site, posterior or anterior, depending on diseased site sampled, PD £3 mm, no BOP, no CAL, no bone loss). Plaque samples were harvested using sterile absorbent endodontic paper points ¶ and stored at -80°C until processed.
Bacterial DNA extraction and JP2 sequence detection proceeded, as previously described. 22 Briefly, bacterial DNA was isolated from subgingival plaque samples using a DNA purification kit, following the manufacturer's instructions. # Target sequences were amplified under standard polymerase chain reaction (PCR) conditions using a PCR amplification mix** and primers previously mentioned by Poulsen et al.: 23 ltx3 (59-GCCGACACCAAAGACAAAGTCT-39) and ltx4 (59-GCCCATAACCAAGCCACATAC-39).
Periodontal Treatment
Periodontal treatment methods used in this study were performed by two calibrated examiners (LMS and PH), as previously described in detail. 24 Treatment was administered subsequent to recording baseline periodontal parameters/sample collection and consisted of a full-mouth supra-and subgingival debridement using an ultrasonic device † † and SRP of diseased sites under local anesthesia, as needed. Additionally, patients were prescribed one single regimen of systemic antibiotics: a combination of 500 mg amoxicillin (AMOX) and 250 mg metronidazole (MET) [25] [26] [27] (dosage adjusted for children <40 kg), three times daily for 7 days. Antibiotic compliance and side effects were verified at the next visit with patient/parent, returned medication bottles, and medication log. All patients received oral hygiene instructions and an accompanying oral care kit consisting of an electronic toothbrush, ‡ ‡ toothpaste, dental floss, and interproximal brushes, as needed. Participants were requested to be present at 3-, 6-, and 12-month appointments after baseline for reexamination, at which they received additional fullmouth supra-and subgingival debridement with an ultrasonic device, SRP of remaining diseased sites as needed, and oral hygiene instructions. Patients did not receive additional antibiotics at follow-up visits.
Statistical Analyses
Power analysis for this study was determined by baseline differences between patients with LAgP and controls, as described previously. 22 Post hoc power analysis, run for the x 2 test for the main outcome variable (presence of JP2 after treatment in diseased sites), showed a power of 89.6% for the lowest number of patients (31 at 12 months). Statistical analyses of the presence of JP2 and non-JP2 strains and correlations with clinical parameters were conducted using statistical software. § § x 2 and Fisher exact tests were used to compare prevalence of positive strains (JP2 and non-JP2) at each time point, before and after treatment, out of total available sites (no data imputing performed). Pearson/ Spearman correlations were used to correlate clinical 
RESULTS
Sixty patients were included in this study. Baseline analysis of JP2 genotype prevalence within this group has been recently published. 22 An impressive 83% of this study population carried the JP2 genotype in either a diseased site (75%) or a healthy site (56.67%). The non-JP2 sequence proved to be significantly less pronounced within this group, presenting in only 18.33% of both diseased and healthy sites. Coinfection with JP2 and non-JP2 sequences was observed in 15% of diseased and healthy sites. 22 Among the 60 participants enrolled at baseline, 40 (66.67%) returned at 3 months for post-treatment evaluation and 31 (51.67%) returned at both 6 and 12 months (Table 1) . A significant reduction in prevalence of Aa was observed after periodontal treatment. At 3, 6, and 12 months after therapy, detection of the JP2 genotype in LAgP diseased sites had reduced to 17.5% (7/40), 6.45% (2/31), and 3.23% (1/31), respectively, compared with 75% at baseline (P <0.001; Fig. 1A ). In LAgP healthy sites, post-treatment JP2 detection rate was 2.5%, 3.23% and 0% at 3, 6, and 12 months, respectively, compared with 56.67% at baseline (P <0.001; Fig. 1B) . In diseased sites, non-JP2 sequence prevalence also reduced from 18.33% at baseline to 0% at 3 months and to 3.23% at both 6 and 12 months (P <0.01; Fig. 2A) . In healthy sites, non-JP2 sequence prevalence reduced from 18.33% at baseline to 2.5% at 3 months and 3.23% at both 6 and 12 months (P <0.01; Fig. 2B ). Interestingly, taking into consideration only those 31 patients who were evaluated at 12 months, their baseline proportion of diseased sites with the JP2 clone is 68% (21 total), and only one patient of those 31 (3%) presented this species at 12 months after therapy (P <0.001).
Similarly, significant improvements were also observed in PD and CAL after treatment (Fig. 3A) . At baseline, mean PD and CAL values for LAgP diseased sites measured 6.55 and 3.98 mm, respectively. Post-therapy evaluations at 3, 6, and 12 months reported reductions, with the following mean values: 4.45, 4.32, and 4.61 mm for PD and 1.75, 1.84, and 1.84 mm for CAL, respectively (P <0.001; Fig. 3A) . Reductions in BOP were also noted across posttreatment time points, but they were non-significant (Table 1) . Baseline data before therapy showed no significant difference between mean PD and mean CAL of LAgP diseased sites that were positive and those that were negative for the JP2 sequence. 22 However, after treatment, significant positive correlations were observed between JP2 presence and PD (P = 0.002; r 2 = 0.2889) and between JP2 presence and CAL (P <0.001; r 2 = 0.3619). Significant difference was noted between PD and CAL of sites with and without the JP2 sequence at baseline and PD and CAL of the same sites at subsequent visits (P <0.001); markedly, as the number of JP2-positive sites decreased due to treatment, so did PD and CAL readings (Fig. 3B) . It is important to note that there were no reported side effects with the use of this regimen by any participant.
DISCUSSION
Research describes microbiologic environments associated with periodontal health as a homeostatic balance in which potentially pathogenic species are presumed to naturally exist within indigenous microflora. Colonization by these pathogens is kept to a minimum due to competition from commensal species. 28 However, slight disturbances in the subgingival environment may be disruptive to this homeostasis, thereby enabling antagonistic species to thrive and outcompete commensal ones. Such shifts in microbial ecosystems are believed to be the driving forces behind development of inflammatory diseases of the periodontium. [28] [29] [30] Microbial analyses of subgingival microflora of patients with LAgP indicate that these individuals maintain a collection of organisms that is significantly different from that of healthy individuals. 31 Specifically, within African-American adolescent populations, presence of the highly virulent JP2 genotype of Aa has garnered much attention; this species, as evidenced by a number of studies, appears to be strongly implicated in the etiology of LAgP in this group. 9, [31] [32] [33] [34] Findings from a preliminary investigation concerning prevalence of the JP2 genotype in 60 African-American patients with LAgP further substantiates this claim, as 83% of this study population harbored the highly leukotoxic JP2 genotype. 22 This study evaluates the impact of periodontal treatment on stability of the JP2 genotype of Aa, as it relates to the effectiveness of treatment on clinical presentation of LAgP within this group.
Results of the present study are consistent with previous treatment studies that have reported positive correlation between reduction of Aa and resolution of LAgP. 17, 35 Considering LAgP diseased and healthy sites in the present study, significant reductions were observed in detectability of the JP2 and non-JP2 sequences after mechanical debridement and antibiotic
ii GraphPad Prism, GraphPad Software. therapy ( Figs. 1 and 2) . Correlation between diseased sites harboring or not harboring the JP2 sequence at baseline alone was not significant with regard to mean PD and CAL in those sites; this could be due to too few LAgP sites negative for JP2 (15) compared with those positive for JP2 (45), and the disease being clinically very uniform among those sites (all sites deeper than 5 mm). However, after treatment, correlation was found between JP2 and both PD and CAL; that is, sites with persistent JP2 sequence after treatment presented significantly deeper PD and higher CAL than the JP2-negative sites (Fig. 3) . Furthermore, elimination of the JP2 genotype (conversion of a site from JP2-positive to JP2-negative) in the long term after treatment corresponded to improvements and maintenance in clinical presentation of LAgP. Specifically, both PD and CAL measurements were significantly reduced after treatment and remained reduced for £12 months after therapy. These results corroborate previous findings, where elimination of JP2 was correlated with positive clinical presentation. 21 These correlations presented here provide further evidence for implication of the JP2 genotype as an associated pathogen in LAgP disease, attesting for the first time the effectiveness of this non-surgical treatment protocol for this population at 12 months after therapy. In fact, longterm clinical benefits and 4-year maintenance of this treatment protocol has been previously reported for all patients with LAgP in another trial. 36 It is noteworthy that this is a one-time regimen of antibiotics for treatment of this population at baseline, and the patients are followed by regular maintenance after this treatment. Thus, significant reduction of this pathogen in the long term with one-time antibiotic use is of extreme clinical benefit for this disease. The aforementioned treatment study by Cortelli et al. 21 presents results comparable to the present study. Furthermore, these authors report that patients infected with the non-JP2 genotype appeared to respond more favorably to treatment than those infected with the JP2 genotype. Reductions in detectability of the non-JP2 clone of Aa were also observed in the present study 12 months after treatment; however, the non-JP2 genotype was only present in 28.33% of sites in the present study, the majority of which occur as a coinfection with the JP2 sequence. Thus, it was not possible to statistically compare effects of non-JP2 alone in response to treatment in the present investigation. However, the present study results regarding JP2 do corroborate this earlier investigation, as previously mentioned.
The JP2 genotype was also detected in 56.67% of healthy sites examined at baseline, and significant reduction in the presence of the JP2 genotype was also observed in these sites after treatment. The notable presence of this bacterium in healthy sites of patients with LAgP and in the healthy control group (40%) analyzed previously 22 indicates that simply detecting the JP2 sequence may not be sufficient to predict disease onset. Nonetheless, presence of this bacterial genotype may increase host susceptibility for commensal-pathogen imbalance. This, along with genetic predisposition and heightened host responsiveness, 37 may lead to disease onset. It is interesting to also note here that the previous study looking at a slightly smaller sample size of the present study cohort (51 patients with LAgP) and under a 16S-ribosomal RNA microarray-based assay (human oral microbe identification microarray) has shown >50% of diseased sites harboring Aa (OT531) in this population, 31 although the specific JP2 genotype evaluated here was more prevalent, as detected with regular PCR (75% of diseased sites). It is also important to note that the detection rate of this species after treatment could have A) ANOVA (Kruskal-Wallis with Dunn multiple comparisons) shows significant differences between baseline (BL) mean PD and mean CAL of sampled diseased site and all other time points, £12 months (*P <0.001). B) Spearman correlation shows significant positive correlation between JP2 (JP2+) presence and PD (r 2 = 0.2889; P = 0.002) and CAL (r 2 = 0.3619; P <0.001), and Mann-Whitney U test shows significant difference between JP2-positive (JP2+) and JP2-negative (JP2-) sites in terms of PD ( ‡ P = 0.002) and CAL (*P <0.001).
been higher if more sites were collected at baseline and after treatment. 38 However, given the localization of this specific disease (only some sites in the mouth were affected), attrition data (missed appointments after treatment, which is a common occurrence for this population), and the very low prevalence of this disease, collection of a higher number of post-treatment samples was not possible in the present investigation. Additionally, some patients failed to present at all time points and therefore, lack of proper maintenance could potentially lead to recurrence of JP2 colonization. However, despite these limitations, it is important to note that the present study still shows high prevalence of JP2 at baseline, followed by a very low detection rate of this species after treatment, with a power of >80%.
Another limitation in this study is the lack of quantification of actual bacterial load within the sites analyzed. This study only evaluates presence/absence of this species. The actual amount of this species load in the sites could potentially influence onset and severity of LAgP manifestation and, consequently, strongly influence response to treatment. However, the present study shows that this treatment protocol was able to significantly reduce detection of JP2 in LAgP and maintain low detection rates, along with clinical stability, over 12 months after therapy.
CONCLUSIONS
This study shows that mechanical periodontal therapy with a single regimen of AMOX and MET was successful in reducing and maintaining a low rate of detection of JP2 in diseased and healthy sites of African-American adolescents diagnosed with LAgP, along with significant reduction and stability of clinical parameters of the disease, 12 months after therapy.
